Although the three studies all aim to advance AD research, you will find differences in participant pools, and adjustments to data collection protocols over time as a result of scientific findings and changing technologies. These differences are outlined in the Study Objectives, and the Data & Samples sections for each core. For instance, DTI data is available from some ADNI GO and ADNI 2 subjects, as this is fairly new technology. ADNI manuals, procedures are protocols from each study are available on the ADNI Documents: Procedures, Protocols, and Manuals webpage for download.
Please visit the Alzheimer’s Disease Education and Referral (ADEAR) Center Website for a listing of open clinical studies. You can sign up at one of our acquisition site locations, in the US or Canada. Browse our map on the Acquisition Site page.
A biomarker, or biological marker, is a substance, measurement or indicator of a biological state. Biomarkers may exist before clinical symptoms arise. ADNI uses various biomarkers to help predict the onslaught of Alzheimer’s disease. Read more about biomarkers on the study Background & Rationale webpage.
Mike Weiner is the principle investigator of ADNI. Read his bio and get his contact information from the Administrative Core webpage.